Wednesday 12 January 2011

High doses of common painkillers increase stroke risk, warn researchers

British Medical Journal study links ibuprofen to highest risk of stroke over long term
The Guardian, 
Tablets
Experts looked at 30 clinical trials to examine the effects of painkillers on health. Photograph: Nitschkefoto / Alamy/Alamy
Commonly used painkillers increase the risk of heart attacks and strokes when taken at high doses or over the long term, according to research.
Experts analysed more than 30 clinical trials on more than 116,000 patients to examine the effects of painkillers on people's health.
The fears relate to non-steroidal anti-inflammatory drugs as well as newer anti-inflammatory drugs known as Cox-2 inhibitors.
Doctors regularly prescribe such drugs to treat painful conditions, including osteoarthritis.
They are given at much higher doses than those found in over-the-counter remedies, which are used for occasional headaches, aches and pains.
The study, in the British Medical Journal, found that compared with a dummy drug lumiracoxib increased the risk of heart attacks, while ibuprofen was linked to the highest risk of stroke (more than treble the risk).
Diclofenac almost tripled the risk, while etoricoxib and diclofenac were associated with around a fourfold increased risk of suffering death from cardiovascular causes.
The authors, from the University of Bern in Switzerland, said: "Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms."
In an accompanying editorial, Prof Wayne Ray, from the department of preventive medicine in Nashville, said: "Naproxen seemed least harmful.
"Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug."
Overall, the number of heart attacks and strokes reported was low compared to the number of patients.
In 29 of the trials, there were a total of 554 heart attacks and in 26 trials there were 377 strokes. In 28 trials there were 676 deaths.

No comments:

Post a Comment